{"title":"如何使FDA专员的新药审查项目成为一股力量，为患者提供负担得起的药物。","authors":"Sarah K Emond, Daniel A Ollendorf","doi":"10.1093/haschl/qxaf182","DOIUrl":null,"url":null,"abstract":"<p><p>The FDA Commissioner's new National Priority Voucher program seeks to accelerate drug approvals for products meeting certain criteria. Interestingly, the program intends to increase affordability of new drugs. With few specifics available as to how the program will achieve that goal, this paper proposes a framework for leveraging independent value assessments to achieve affordable access while incentivizing evidence development and innovation.</p>","PeriodicalId":94025,"journal":{"name":"Health affairs scholar","volume":"3 10","pages":"qxaf182"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492479/pdf/","citationCount":"0","resultStr":"{\"title\":\"How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients.\",\"authors\":\"Sarah K Emond, Daniel A Ollendorf\",\"doi\":\"10.1093/haschl/qxaf182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The FDA Commissioner's new National Priority Voucher program seeks to accelerate drug approvals for products meeting certain criteria. Interestingly, the program intends to increase affordability of new drugs. With few specifics available as to how the program will achieve that goal, this paper proposes a framework for leveraging independent value assessments to achieve affordable access while incentivizing evidence development and innovation.</p>\",\"PeriodicalId\":94025,\"journal\":{\"name\":\"Health affairs scholar\",\"volume\":\"3 10\",\"pages\":\"qxaf182\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492479/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health affairs scholar\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/haschl/qxaf182\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health affairs scholar","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/haschl/qxaf182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
How to make one line in the FDA Commissioner's new drug review program into a force for affordable access for patients.
The FDA Commissioner's new National Priority Voucher program seeks to accelerate drug approvals for products meeting certain criteria. Interestingly, the program intends to increase affordability of new drugs. With few specifics available as to how the program will achieve that goal, this paper proposes a framework for leveraging independent value assessments to achieve affordable access while incentivizing evidence development and innovation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
